Abbott Launches NeuroSphere Virtual Clinic For Remote Neurostim Programming
The US FDA approved Abbott's system that allows physicians to communicate with patients and remotely program their neuromodulation device.
You may also be interested in...
The newly approved Proclaim Plus system allows physicians to treat as many as six independent pain sites and choose the lowest-possible effective dose for each site.
Abbott continued St. Jude Medical’s prior research on deep brain stimulation for treating depression and has advanced the technology far enough that the US FDA now believes it could be a breakthrough treatment for treatment-resistant depression.
The GUIDE HF investigators contend the trial missed its primary endpoint because of COVID-19.